Evidence map›Paper›PMID 40535844›Full record

ReviewJournal of clinical and experimental hepatology

Adoption of the New Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by the Indian National Association for Study of the Liver (INASL): Implications for the INASL Guidance Paper on NAFLD.

Ajay Duseja, Arka De, Shivaram P Singh, Kaushal Madan, Padaki N Rao, Akash Shukla, Gourdas Choudhuri, Sanjiv Saigal, Shalimar, Anil Arora and 20 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Ajay DusejaDepartment of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Arka DeDepartment of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Shivaram P SinghDigestive Diseases Centre, Cuttack, India.
Kaushal MadanMax Centre for Gastroenterology, Hepatology and Endoscopy, Max Hospitals, Saket, New Delhi, India.
Padaki N RaoDepartment of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India.
Akash ShuklaDepartment of Gastroenterology, Seth GSMC & KEM Hospital, Mumbai, India.
Gourdas ChoudhuriDepartment of Gastroenterology and Hepato-Biliary Sciences, Fortis Memorial Research Institute, Gurugram, India.
Sanjiv SaigalMax Centre for Gastroenterology, Hepatology and Endoscopy, Max Hospitals, Saket, New Delhi, India.
ShalimarDepartment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.
Anil AroraInstitute of Liver, Gastroenterology and Pancreatico-Biliary Sciences, Sir Ganga Ram Hospital, New Delhi, India.
Anil C AnandDepartment of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar, India.
Ashim DasDepartment of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Ashish KumarInstitute of Liver, Gastroenterology and Pancreatico-Biliary Sciences, Sir Ganga Ram Hospital, New Delhi, India.
Chundamannil E EapenDepartment of Hepatology, Christian Medical College, Vellore, India.
Krishnadas DevadasDepartment of Gastroenterology, Government Medical College, Trivandrum, India.
Kotacherry T ShenoyDepartment of Gastroenterology, SreeGokulam Medical College, Trivandrum, India.
Manas PanigrahiDepartment of Gastroenterology, All India Institute of Medical Sciences, Bhubaneswar, India.
Manav WadhawanInstitute of Liver & Digestive Diseases, BLK Super Speciality Hospital, Delhi, India.
Manish RathiDepartment of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Narendra S ChoudharyDepartment of Hepatology, Medanta, The Medicity, Gurugram, India.
Neeraj SarafDepartment of Hepatology, Medanta, The Medicity, Gurugram, India.
Preetam NathDepartment of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar, India.
Sanjib KarDepartment of Gastroenterology and Hepatology, Gastro Liver Care, Cuttack, India.
Seema AlamDepartment of PediatricHepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
Samir ShahDepartment of Hepatology, Institute of Liver Disease, HPB Surgery and Transplant, Global Hospitals, Mumbai, India.
Sandeep NijhawanDepartment of Gastroenterology, Sawai Man Singh Medical College, Jaipur, India.
Subrat K AcharyaDepartment of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar, India.
Vinayak AggarwalDepartment of Cardiology, Fortis Memorial Research Institute, Gurugram, India.
Vivek A SaraswatDepartment of Hepatology, Pancreatobiliary Sciences and Liver Transplantation, Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, India.
Yogesh K ChawlaDepartment of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transition from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) reflects a paradigm shift in hepatology, emphasising metabolic dysfunction as the central driver in patients with MASLD. This inclusive terminology, endorsed by over 70 international organisations including the Indian National Association for Study of the Liver (INASL), reduces stigma of 'fatty and alcohol' and allows the co-existence of other liver disease etiologies along with MASLD. In the present commentary, we discuss the implications of the adoption of new nomenclature of MASLD on the INASL guidance paper on NAFLD, which was published in 2023, before the Delphi consensus on MASLD.

Indexed as

cryptogenic cirrhosismetabolic dysfunction-associated steatotic liver disease (MASLD)nonalcoholic fatty liver disease (NAFLD)nonalcoholic steatohepatitis (NASH)

Identifiers

PMID40535844
PMCPMC12173646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.